The Salk Institute for Biological Studies

Sanford Burnham Prebys Medical Discovery Institute

Southern Research Institute

Sanford-burnham Medical Research Institute

Peter Teriete

Nicholas David Peter Cosford

Mitchell Dennis Vamos

John A T Young

Sumit K Chanda

John M Marlett

Lars Pache

Arturo Diaz

Nicholas D P Cosford

Marintha L Heil

Nicholas Pagano

John At Young

John AT Young

Nicholas DP Cosford

John Marlett

Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV).

Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy

Provided herein is the use of compounds that modulate the activity of inhibitor of apoptosis proteins (IAPs), alone or in combination with other therapeutic agents, in the treatment of human immunodeficiency virus (HIV). Described herein is the use of IAP antagonists in the treatment of human immunodeficiency virus (HIV) in a mammal, alone or in combination with other therapeutic agents used in HIV therapy. In one aspect, provided herein is a method of treating human immunodeficiency virus (HIV) in an individual in need thereof comprising administering a therapeutically effective amount of at least one inhibitor of apoptosis proteins (IAP) antagonist.

Compounds of Formula (I) wherein B is selected from the group consisting of substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; Y is a linker moiety selected from the group consisting of a direct bond. R, R1, R2, and R3 are each individually selected from the group consisting substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or heterocycle.

HIV replication inhibitors

Growing community of inventors

La Jolla, CA, United States of America

Peter Teriete